Phoreus Biotech launches BAPtofect®-25 peptide transfection reagent as a superior alternative to industry-leading, lipid-based reagents

OLATHE, KS, Mar. 1, 2023 – Phoreus Biotech, a leading provider of next-generation peptide nanocarriers, announced today they’ve added a new product to their portfolio of proprietary transfection reagents. The new BAPtofect-25 for general cell transfection now allows researchers to work with a large variety of cell lines to compliment the company’s previous offerings for use in insect cell lines.

“Researchers have been stuck for too long with using lipid-based transfection reagents that can be very cytotoxic,” said Michael Coe, CSO, Phoreus Biotech. “We’re pleased to present a new option that has a number of advantages over the leading reagents available today.”

Cell transfection is the process of introducing DNA, RNA, or other genetic material into cells to modify or activate those cells. It is a critical step in many areas of research, from gene therapy to vaccine development. Phoreus Biotech has been a provider of transfection reagents for more than four years, and they continue to expand their portfolio with innovative products like BAPtofect-25. This new product allows researchers to work with numerous difficult-to-transfect cell lines, making it an essential tool for any lab working in this field.

The lipid-based transfection reagents that have long served as the industry standard suffer from several serious limitations. While liposomal-based carriers can achieve high transfection rates, there are multiple issues associated with their use in research. Lipid-based carriers tend to be unstable, resulting in a premature breakdown that releases their cargo before reaching the intended destination. Additionally, liposomes can sometimes form aggregates and precipitate out of solution or clump together instead of remaining evenly dispersed throughout the solution. Due to their lack of stability and inherent toxicity to cells, there remains a strong need for better transfection reagent options.

BAPtofect-25 provides extremely high transfection rates, compared to the leading liposomal-based carriers, with expression in nearly all cells. The product also maintains excellent cell viability with virtually no cellular toxicity. Users typically see diffuse transfection in cells, rather than the pinpoint transfection of other reagents. BAPtofect-25 also offers the distinct advantage of being able to move seamlessly from in-vitro research to in-vivo applications, unlike the lipid transfection reagents which differ significantly from the lipid nanoparticles used in modern mRNA vaccines. Phoreus nanocarriers have now been referenced in more than 25 research publications for effective in vitro and in vivo nanodelivery.

“We are fully committed to providing researchers with the best possible tools to improve the important work they conduct every day,” said Steve Schram, CEO, Phoreus Biotech. “BAPtofect-25 is another example of that commitment.”

 About Phoreus Biotech

Phoreus Biotech is an Olathe, KS-based life science company and is the provider of three proprietary nanocarrier platforms with the capacity to revolutionize human, animal, plant, and environmental health. Their Branched Amphipathic Peptide Capsules (BAPC®), Corralling Amphipathic Peptide Capsules (CAPC®), and Amphipathic Peptide Capsules (APC®) offer substantially increased efficacy in the creation and delivery of vaccines, cancer therapies, antibiotics, diagnostics, and biopesticides.